IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IOVANCE BIOTHERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.21+0.59 (+4.33%)
Close on Oct 19, 2026
- Market cap
- $6.40M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
63.3%
287M of 453M shares
Institutional holders
292
45 new, 35 sold out
Net institutional buying
18M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 33,366,587 | 7.50% | 13G (passive) amendment | Jun 30, 2026 |
| Wayne P. Rothbaum | 30,000,000 | 11.60% | 13D (active) amendment | Feb 20, 2024 |
| State Street Corporation | 24,478,268 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Mark H. Rachesky, M.D | 20,083,951 | 7.80% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IOVA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 36,957,681 | 8.16% | $153.74M | +5,877,176 | 0.00% |
| Mhr Fund Management LLC | 28,967,103 | 6.39% | $120.50M | – | 6.28% |
| State Street Corp | 24,478,268 | 5.40% | $101.83M | +7,030,160 | 0.00% |
| Two Sigma Investments, LP | 19,010,697 | 4.20% | $79.08M | +5,323,264 | 0.06% |
| Vanguard Capital Management LLC | 18,204,248 | 4.02% | $75.73M | +1,586,511 | 0.00% |
| Vanguard Portfolio Management LLC | 14,388,999 | 3.18% | $59.86M | +2,688,155 | 0.00% |
| Geode Capital Management, LLC | 10,324,826 | 2.28% | $42.96M | +1,752,228 | 0.00% |
| Millennium Management LLC | 8,525,919 | 1.88% | $35.47M | −888,373 | 0.01% |
| Dimensional Fund Advisors LP | 6,460,449 | 1.43% | $26.88M | +3,814,747 | 0.00% |
| Palo Alto Investors LP | 5,296,209 | 1.17% | $22.03M | −1,053,354 | 3.04% |
| Goldman Sachs Group Inc | 5,096,334 | 1.13% | $21.20M | −3,663,726 | 0.00% |
| Nuveen, LLC | 4,997,112 | 1.10% | $20.79M | +1,332,834 | 0.00% |
| Bank Of America Corp /De/ | 4,993,584 | 1.10% | $20.77M | −3,496,535 | 0.00% |
| Morgan Stanley | 4,986,461 | 1.10% | $20.74M | −1,214,821 | 0.00% |
| Jupiter Asset Management Ltd | 4,535,080 | 1.00% | $18.87M | New | 0.09% |
| Jane Street Group, LLC | 4,393,853 | 0.97% | $18.28M | +219,967 | 0.00% |
| Northern Trust Corp | 4,154,200 | 0.92% | $17.28M | +1,278,674 | 0.00% |
| Aqr Capital Management LLC | 3,869,584 | 0.85% | $16.10M | +3,245,416 | 0.01% |
| Wells Fargo & Company/Mn | 3,246,537 | 0.72% | $13.51M | +1,175,013 | 0.00% |
| Charles Schwab Investment Management Inc | 3,219,656 | 0.71% | $13.39M | +435,926 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 292 | 287M | 63.3% | 45 / 132 | 65 / 35 | 53M | 35M |
| Q1 2026 | 286 | 269M | 59.4% | 64 / 122 | 58 / 38 | 73M | 38M |
| Q4 2025 | 263 | 262M | 57.8% | 51 / 104 | 63 / 36 | 61M | 13M |
| Q3 2025 | 253 | 214M | 47.3% | 41 / 83 | 77 / 40 | 27M | 36M |
| Q2 2025 | 255 | 223M | 49.2% | 40 / 93 | 72 / 84 | 50M | 68M |
| Q1 2025 | 302 | 240M | 53.0% | 57 / 101 | 93 / 54 | 39M | 39M |
| Q4 2024 | 301 | 242M | 53.3% | 57 / 101 | 86 / 36 | 28M | 22M |
| Q3 2024 | 286 | 237M | 52.4% | 40 / 107 | 84 / 46 | 52M | 29M |
| Q2 2024 | 295 | 236M | 52.1% | 67 / 114 | 81 / 41 | 39M | 28M |
| Q1 2024 | 273 | 227M | 50.1% | 70 / 91 | 82 / 33 | 48M | 35M |
| Q4 2023 | 236 | 214M | 47.2% | 48 / 87 | 70 / 36 | 27M | 26M |
| Q3 2023 | 227 | 214M | 47.1% | 41 / 107 | 52 / 31 | 45M | 31M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IOVA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 14,493,812 | 3.20% | $60.29M | 0.56% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 13,485,679 | 2.98% | $56.10M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 10,352,918 | 2.29% | $43.07M | 0.05% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 4,858,231 | 1.07% | $20.21M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 4,351,328 | 0.96% | $17.71M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 4,305,078 | 0.95% | $17.91M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 3,723,294 | 0.82% | $15.49M | 0.11% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 3,081,166 | 0.68% | $12.82M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 2,737,376 | 0.60% | $11.39M | 0.13% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 2,707,990 | 0.60% | $11.02M | 0.27% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 2,018,606 | 0.45% | $8.40M | 0.07% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 1,733,813 | 0.38% | $7.11M | 0.04% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 1,727,875 | 0.38% | $7.08M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,615,534 | 0.36% | $6.62M | 0.03% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,439,842 | 0.32% | $5.99M | 0.05% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Frederick G. Vogt | Interim CEO & General Counsel, Director | 595,447 | 0.13% | Sep 10, 2026 |
| Igor Bilinsky | Chief Operating Officer | 142,074 | 0.03% | Sep 10, 2026 |
| Raj K. Puri | Chief Regulatory Officer | 260,842 | 0.06% | Sep 10, 2026 |
| Daniel Gordon Kirby | Chief Commercial Officer | 154,511 | 0.03% | Aug 12, 2026 |
| Corleen M. Roche | Chief Financial Officer | 49,995 | 0.01% | Aug 10, 2026 |
| Finckenstein Friedrich Graf | Chief Medical Officer | 144,087 | 0.03% | Jun 9, 2026 |
| Matthew W. Rosinack | SVP, Finance (Int. PFO & PAO) | 89,129 | 0.02% | Jul 10, 2025 |
| Jean-Marc Bellemin | Chief Financial Officer | 64,993 | 0.01% | Jun 4, 2025 |
| Michael Weiser | Director | 133,303 | 0.03% | Jun 18, 2026 |
| Ryan D. Maynard | Director | 57,500 | 0.01% | Jun 18, 2026 |
| Athena Countouriotis | Director | – | – | Jun 18, 2026 |
| Iain D. Dukes | Director | 54,000 | 0.01% | Jun 18, 2026 |
| Wendy L. Yarno | Director | – | – | Jun 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Raj K. Puri Chief Regulatory Officer | Sep 8, 2026 | Option exercise | +9,766 | – | – | 260,842 |
| Raj K. Puri Chief Regulatory Officer | Sep 8, 2026 | Tax withholding | −4,478 | $8.70 | $38.96K | 256,364 |
| Igor Bilinsky Chief Operating Officer | Sep 8, 2026 | Tax withholding | −3,976 | $8.70 | $34.59K | 142,074 |
| Igor Bilinsky Chief Operating Officer | Sep 8, 2026 | Option exercise | +7,813 | – | – | 146,050 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Sep 8, 2026 | Tax withholding | −6,638 | $8.70 | $57.75K | 595,447 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Sep 8, 2026 | Option exercise | +15,626 | – | – | 602,085 |
| Igor Bilinsky Chief Operating Officer | Sep 1, 2026 | Tax withholding | −4,472 | $8.28 | $37.03K | 138,237 |
| Igor Bilinsky Chief Operating Officer | Sep 1, 2026 | Option exercise | +8,789 | – | – | 142,709 |
| Raj K. Puri Chief Regulatory Officer | Sep 1, 2026 | Tax withholding | −2,508 | $8.28 | $20.77K | 251,076 |
| Raj K. Puri Chief Regulatory Officer | Sep 1, 2026 | Option exercise | +5,470 | – | – | 253,584 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Sep 1, 2026 | Tax withholding | −17,702 | $8.28 | $146.57K | 586,459 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Sep 1, 2026 | Option exercise | +41,669 | – | – | 604,161 |
| Daniel Gordon Kirby Chief Commercial Officer | Aug 10, 2026 | Tax withholding | −2,436 | $6.40 | $15.59K | 154,511 |
| Daniel Gordon Kirby Chief Commercial Officer | Aug 10, 2026 | Option exercise | +10,001 | – | – | 156,947 |
| Corleen M. Roche Chief Financial Officer | Aug 6, 2026 | Option exercise | +49,995 | – | – | 49,995 |
| Corleen M. Roche Chief Financial Officer | Aug 6, 2026 | Tax withholding | −21,238 | $6.21 | $131.89K | 28,757 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Jun 5, 2026 | Tax withholding | −6,638 | $4.23 | $28.08K | 562,492 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Jun 5, 2026 | Option exercise | +15,625 | – | – | 569,130 |
| Finckenstein Friedrich Graf Chief Medical Officer | Jun 5, 2026 | Option exercise | +7,813 | – | – | 144,087 |
| Finckenstein Friedrich Graf Chief Medical Officer | Jun 5, 2026 | Tax withholding | −3,976 | $4.23 | $16.82K | 140,111 |
| Igor Bilinsky Chief Operating Officer | Jun 5, 2026 | Option exercise | +7,813 | – | – | 137,896 |
| Igor Bilinsky Chief Operating Officer | Jun 5, 2026 | Tax withholding | −3,976 | $4.23 | $16.82K | 133,920 |
| Raj K. Puri Chief Regulatory Officer | Jun 5, 2026 | Tax withholding | −3,843 | $4.23 | $16.26K | 248,114 |
| Raj K. Puri Chief Regulatory Officer | Jun 5, 2026 | Option exercise | +9,766 | – | – | 251,957 |
| Raj K. Puri Chief Regulatory Officer | Jun 1, 2026 | Tax withholding | −2,508 | $3.96 | $9.93K | 242,191 |
| Raj K. Puri Chief Regulatory Officer | Jun 1, 2026 | Option exercise | +5,469 | – | – | 244,699 |
| Igor Bilinsky Chief Operating Officer | Jun 1, 2026 | Option exercise | +8,790 | – | – | 134,556 |
| Igor Bilinsky Chief Operating Officer | Jun 1, 2026 | Tax withholding | −4,473 | $3.96 | $17.71K | 130,083 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Jun 1, 2026 | Option exercise | +41,668 | – | – | 571,206 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Jun 1, 2026 | Tax withholding | −17,701 | $3.96 | $70.10K | 553,505 |
| Finckenstein Friedrich Graf Chief Medical Officer | Jun 1, 2026 | Tax withholding | −4,473 | $3.96 | $17.71K | 136,274 |
| Finckenstein Friedrich Graf Chief Medical Officer | Jun 1, 2026 | Option exercise | +8,790 | – | – | 140,747 |
| Daniel Gordon Kirby Chief Commercial Officer | May 11, 2026 | Tax withholding | −2,435 | $3.70 | $9.01K | 146,946 |
| Daniel Gordon Kirby Chief Commercial Officer | May 11, 2026 | Option exercise | +10,000 | – | – | 149,381 |
| Raj K. Puri Chief Regulatory Officer | Mar 5, 2026 | Tax withholding | −18,360 | $4.58 | $84.09K | 239,230 |
| Raj K. Puri Chief Regulatory Officer | Mar 5, 2026 | Option exercise | +39,059 | – | – | 257,590 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Mar 5, 2026 | Tax withholding | −26,755 | $4.58 | $122.54K | 529,538 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Mar 5, 2026 | Option exercise | +62,493 | – | – | 556,293 |
| Igor Bilinsky Chief Operating Officer | Mar 5, 2026 | Tax withholding | −16,628 | $4.58 | $76.16K | 125,766 |
| Igor Bilinsky Chief Operating Officer | Mar 5, 2026 | Option exercise | +31,246 | – | – | 142,394 |
| Finckenstein Friedrich Graf Chief Medical Officer | Mar 5, 2026 | Tax withholding | −16,520 | $4.58 | $75.66K | 131,957 |
| Finckenstein Friedrich Graf Chief Medical Officer | Mar 5, 2026 | Option exercise | +31,246 | – | – | 148,477 |
| Igor Bilinsky Chief Operating Officer | Mar 2, 2026 | Tax withholding | −6,903 | $3.79 | $26.16K | 111,148 |
| Igor Bilinsky Chief Operating Officer | Mar 2, 2026 | Option exercise | +12,307 | – | – | 118,051 |
| Finckenstein Friedrich Graf Chief Medical Officer | Mar 2, 2026 | Option exercise | +12,697 | – | – | 124,353 |
| Finckenstein Friedrich Graf Chief Medical Officer | Mar 2, 2026 | Tax withholding | −7,122 | $3.79 | $26.99K | 117,231 |
| Raj K. Puri Chief Regulatory Officer | Mar 2, 2026 | Tax withholding | −2,798 | $3.79 | $10.60K | 218,531 |
| Raj K. Puri Chief Regulatory Officer | Mar 2, 2026 | Option exercise | +5,470 | – | – | 221,329 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Mar 2, 2026 | Tax withholding | −22,809 | $3.79 | $86.45K | 493,800 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Mar 2, 2026 | Option exercise | +52,087 | – | – | 516,609 |
| Daniel Gordon Kirby Chief Commercial Officer | Feb 24, 2026 | Tax withholding | −34,165 | $3.78 | $129.14K | 139,381 |
| Daniel Gordon Kirby Chief Commercial Officer | Feb 24, 2026 | Option exercise | +120,000 | – | – | 173,546 |
| Daniel Gordon Kirby Chief Commercial Officer | Feb 10, 2026 | Tax withholding | −16,450 | $2.60 | $42.77K | 53,546 |
| Daniel Gordon Kirby Chief Commercial Officer | Feb 10, 2026 | Option exercise | +39,996 | – | – | 69,996 |
| Finckenstein Friedrich Graf Chief Medical Officer | Dec 2, 2025 | Option exercise | +3,906 | – | – | 113,640 |
| Finckenstein Friedrich Graf Chief Medical Officer | Dec 2, 2025 | Tax withholding | −1,984 | $2.14 | $4.25K | 111,656 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Dec 2, 2025 | Tax withholding | −4,426 | $2.14 | $9.47K | 464,522 |
| Frederick G. Vogt Interim CEO & General Counsel, Director | Dec 2, 2025 | Option exercise | +10,417 | – | – | 468,948 |
| Igor Bilinsky Chief Operating Officer | Dec 2, 2025 | Option exercise | +3,516 | – | – | 107,530 |
| Igor Bilinsky Chief Operating Officer | Dec 2, 2025 | Tax withholding | −1,786 | $2.14 | $3.82K | 105,744 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ryan D. Maynard Director | Nov 12, 2024 | 50,000 | $503.10K | Nov 12, 2024 | Stock Option (right to buy) |